Research Article

Related GMR Articles

04/30/2015
Chemotherapy; Clinical outcome; Osteosarcoma; Vascular endothelial growth factors

We investigated the association between vascular endothelial growth factor (VEGF) gene +1612G/A, -634C/G, and +936G/C and the clinical outcome of osteosarcoma. Genomic DNA was isolated from blood samples, and 3 VEGF gene polymorphisms (+1612G/A, -634C/G, and +936G/C) were analyzed using polymerase chain reaction-restriction fragment length polymorphism. Of the 194 patients, 82 patients ( ... more

X.D. Li; D.D. Yu; J.R. Lu; C. Wu; W.X. Jin
06/11/2015
Breast cancer; Ethnicity; Glutathione S-transferases; Northeastern Mexico; Polymorphisms

Glutathione S-transferases (GSTs) are a family of phase II metabolizing enzymes involved in carcinogen detoxification and the metabolism of various bioactive compounds. Several genes that code for these enzymes are polymorphic in an ethnicity-dependent manner, with particular genotypes previously associated with an increased risk of breast cancer. The purpose of this study was to ... more

G. Jaramillo-Rangel; M. Ortega-Martínez; R.M. Cerda-Flores; H.A. Barrera-Saldaña
07/24/2014
BRCA1; Clinical outcome; Non-small cell lung cancer; RRM1

This study aimed to evaluate the association between RRM1 and BRCA1 expressions and the therapeutic efficacy of platinum-based chemotherapy in non-small cell lung cancer patients in terms of their response and prognosis. In total, 377 patients agreed to participate in our study, and all of them received platinum-based combination chemotherapy between January 2008 and ... more

J.G. Liang; Z.Y. Jin; X.D. Gao; M.R. Te; L.H. Ge; C.L. Wang
05/16/2014
Clinical outcome; Hepatocellular carcinoma; Polymorphism; susceptibility; XPD; XRCC1

We explored the association between 4 XRCC1 (Arg194Trp and Arg399Gln) and XPD (Asp312Asn and Lys751Gln) polymorphisms with the development and prognosis of hepatocellular carcinoma (HCC). A total of 218 cases with HCC and 277 healthy controls were included in the study. Genotyping of the XRCC1 (Arg194Trp and Arg399Gln) and XPD (Asp312Asn and Lys751Gln) polymorphisms was ... more

J.S. Wu; Y.P. Chen; L.C. Wang; Y.J. Yang; C.W. Deng; B.X. Hou; Z.L. He; J.X. Chen
04/19/2005
Fab; Human antibody repertoire; Osteosarcoma; Phage display; Recombinant antibody

Osteosarcoma is the commonest type of primary malignant bone tumor, frequently found in adolescents at sites of rapid bone growth. Despite current management protocols, up to half of the patients succumb to this disease. Moreover, there is no well-characterized molecular marker for diagnosis and prognosis. Since phage display methodology allows the selection of human antibody fragments with ... more

C. Dantas-Barbosa; M.M. Brígido; A.Q. Maranhão
03/01/2012
Bone neoplasms; Osteochondroma; Osteosarcoma

Osteochondroma is a cartilage capped benign tumor developing mainly at the juxta-epiphyseal region of long bones. The rate of malignant transformation, mainly into chondrosarcoma, is estimated to be less than 1-3%. Transformation into osteosarcoma is very rare and has been reported only thirteen times. There is little information on treatment and outcome. We report the case of a secondary ... more

E.E. Engel; M.H. Nogueira-Barbosa; M.S. Brassesco; G.E.B. Silva; E.T. Valera; F.M. Peria; T.C. Motta; L.G. Tone
07/24/2014
Drug resistance; Methotrexate; Osteosarcoma; Reduced folate carrier

Osteosarcoma is a primary malignant tumor in adolescents, associated with high mortality and morbidity. The high-dose methotrexate (MTX) chemotherapy used to treat this disease may induce primary or secondary drug resistance, resulting in a reduced effect of comprehensive treatment. In this study, the relationship between reduced folate carrier (RFC) gene expression and intracellular drug ... more

J.J. Wang; G.J. Li
03/13/2015
Osteosarcoma; Polymorphism; RECQL5

In this study, we investigated the association between a RECQL genetic polymorphism and osteosarcoma in a Chinese population. We selected rs820196 in the RECQL5 gene and genotyped 185 patients with osteosarcoma and 201 age- and gender-matched non-cancer controls. We found that the CC genotype was more frequent in the osteosarcoma group compared to the control group (P = ... more

Y.Z. Dong; Y.X. Huang; T. Lu
05/14/2013
Genetic polymorphism; Glioma; Glutathione S-transferases; Perillyl alcohol

GSTM1 (glutathione S-transferase mu 1) and GSTT1 (glutathione S-transferase theta 1) are critical enzymes for detoxification of endogenous and environmental carcinogens. Constitutive GST gene polymorphisms may be associated with increased risk for cancer development. We made an explorative study of a Brazilian population with malignant glioma to determine whether ... more

M.M. Silva; C.O. Da Fonseca; R. Moura-Neto; J.F. Carvalho; T. Quirico-Santos; M.G. Carvalho
09/22/2015
Chemotherapy; Clinical outcome; Glutathione S-transferases; Polymorphism

The aim of this study was to evaluate the role of GSTM1 null/present, GSTT1 null/present, and GSTP1 IIe105Val polymor­phisms in the clinical response to chemotherapy and treatment outcome of patients with breast cancer. A total of 262 subjects were randomly selected from among patients with a histologically confirmed breast cancer. The genotypes of GSTM1, ... more

J. Wang; T. Wang; G.Y. Yin; L. Yang; Z.G. Wang; X.B. Bu

Pages